In the past week, ADMA stock has gone up by 1.90%, with a monthly decline of -7.89% and a quarterly plunge of -10.12%. The volatility ratio for the week is 4.08%, and the volatility levels for the last 30 days are 4.29% for Adma Biologics Inc The simple moving average for the past 20 days is -6.86% for ADMA’s stock, with a -3.45% simple moving average for the past 200 days.
Is It Worth Investing in Adma Biologics Inc (NASDAQ: ADMA) Right Now?
Adma Biologics Inc (NASDAQ: ADMA) has a higher price-to-earnings ratio of 21.57x compared to its average ratio, The 36-month beta value for ADMA is at 0.44. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADMA is 230.52M, and currently, shorts hold a 5.99% of that float. The average trading volume for ADMA on July 01, 2025 was 3.60M shares.
ADMA) stock’s latest price update
Adma Biologics Inc (NASDAQ: ADMA)’s stock price has plunge by 0.28relation to previous closing price of 18.16. Nevertheless, the company has seen a 1.90% surge in its stock price over the last five trading sessions. zacks.com reported 2025-06-27 that Adma Biologics (ADMA) closed at $18.16 in the latest trading session, marking a -1.3% move from the prior day.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at -11.53% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.06% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from Grossman Adam S, who sale 21,000 shares at the price of $20.81 back on Jun 16 ’25. After this action, Grossman Adam S now owns 2,043,850 shares of Adma Biologics Inc, valued at $437,010 using the latest closing price.
ELMS STEVE, the Director of Adma Biologics Inc, sale 194,749 shares at $20.24 during a trade that took place back on Jun 16 ’25, which means that ELMS STEVE is holding 87,330 shares at $3,941,720 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.33 for the present operating margin
- 0.53 for the gross margin
The net margin for Adma Biologics Inc stands at 0.45. The total capital return value is set at 0.33. Equity return is now at value 78.45, with 48.01 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 1.23. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 18.57.
Currently, EBITDA for the company is 147.69 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 9.49. The receivables turnover for the company is 4.62for trailing twelve months and the total asset turnover is 0.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.58.
Conclusion
In conclusion, Adma Biologics Inc (ADMA) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
